OIL has Zeiss absorbing all the marketing for the neuro digital...

OIL has Zeiss absorbing all the marketing for the neuro digital biopsy tool (Convivo) and management have said they expect "a significantly improved performance for the 2017/18 period and beyond." I would expect OIL will be at least cash flow positive by end of 2017/18 FY. That is something MK are still to achieve.

I see that MK as of a couple of minutes ago are still going up
https://www.marketwatch.com/investing/stock/mkea?countrycode=fr

The US reimbursement has increased for endomicroscopy, that can`t do any harm on the road to "optical biopsy" which will be trail blazed in Neurosurgery by Zeiss over coming months. It will only be a matter of time before OIL knocks  or someone comes knocking at OIL wanting to get involved in other areas including Gastro.

In the meantime the "value anomaly" first identified by Gus Holt many moons ago is there see.